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Abstract
Background
Plasmodiummalariae is a slow-growing parasite with a wide geographic distribution.
Although generally regarded as a benign cause of malaria, it has been associated with
nephrotic syndrome, particularly in young children, and can persist in the host for years.
Morbidity associated with P.malariae infection has received relatively little attention, and
the risk of P.malariae-associated nephrotic syndrome is unknown.
Methodology/Principal Findings
We used data from a very large hospital-based surveillance system incorporating informa-
tion on clinical diagnoses, blood cell parameters and treatment to describe the demographic
distribution, morbidity and mortality associated with P.malariae infection in southern Papua,
Indonesia. Between April 2004 and December 2013 there were 1,054,674 patient presenta-
tions to Mitra Masyarakat Hospital of which 196,380 (18.6%) were associated with malaria
and 5,097 were with P.malariae infection (constituting 2.6% of all malaria cases). The pro-
portion of malaria cases attributable to P.malariae increased with age from 0.9% for patients
under one year old to 3.1% for patients older than 15 years. Overall, 8.5% of patients with P.
malariae infection required admission to hospital and the median length of stay for these
patients was 2.5 days (Interquartile Range: 2.0–4.0 days). Patients with P.malariae infec-
tion had a lower mean hemoglobin concentration (9.0g/dL) than patients with P. falciparum
(9.5g/dL), P. vivax (9.6g/dL) and mixed species infections (9.3g/dL). There were four cases
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of nephrotic syndrome recorded in patients with P.malariae infection, three of which were in
children younger than 5 years old, giving a risk in this age group of 0.47% (95% Confidence
Interval; 0.10% to 1.4%). Overall, 2.4% (n = 16) of patients hospitalized with P.malariae
infection subsequently died in hospital, similar to the proportions for the other endemic Plas-
modium species (range: 0% for P. ovale to 1.6% for P. falciparum).
Conclusions/Significance
Plasmodiummalariae infection is relatively uncommon in Papua, Indonesia but is associ-
ated with significant morbidity from anemia and a similar risk of mortality to patients hospital-
ized with P. falciparum and P. vivax infection. In our large hospital database, one in 200
children under the age of 5 years with P.malariae infection were recorded as having
nephrotic syndrome.
Author Summary
Plasmodium malariae is a relatively rare, but widely distributed, cause of malaria. It can
persist in the human host for years, often without causing significant symptoms. As a
result, P.malariae will be a very difficult species to eradicate. Our study used data from a
routine hospital-based surveillance system in southern Papua, Indonesia to describe the
clinical epidemiology of P.malariae infections. Over a 10-year period there were 5,097
patient presentations to Mitra Masyarakat Hospital associated with P.malariae infection
constituting 2.6% of all malaria cases. Patients with P.malariaemalaria had a significantly
older age distribution than those with P. vivax infections. They also had lower mean
hemoglobin concentrations than patients infected with P. falciparum, P. vivax or mixed
Plasmodium species. We speculate that this may be due to chronic hemolysis of parasitized
and non-parasitized red cells as a result of persistent infection. One in 200 children under
the age of 5 years with P.malariae infection were recorded as having nephrotic syndrome,
a well-known but to date unquantified complication. Overall, 0.3% of patients with P.
malariae malaria died. These findings emphasize the need to consider this parasite when
designing comprehensive malaria elimination strategies.
Introduction
Plasmodium malariae is one of the five Plasmodium species that commonly infect humans.
The global incidence of infection by this species is unknown but is thought to be significantly
lower than for P. falciparum [1]. Plasmodium malariae is endemic in parts of Africa [2–4],
South America [5, 6], Asia [7–10] and the Western Pacific [11]. Infection is often asymptom-
atic [12] and severe disease is thought to be rare. However, untreated infection has been
reported to lead to nephrotic syndrome [13–15] and albuminuria was commonly noted in
patients treated with P.malariae for neurosyphilis in the 1930s [16]. Given the parasite’s ability
to survive in the human host at low parasitemias for decades [17], chronic morbidity related to
P.malariae infection is likely to occur.
Global malaria elimination strategies justifiably target P. falciparum, which is associated
with the greatest risk of acute morbidity and mortality. When such malaria control strategies
are successful, the fall in P. falciparum endemicity is often associated with a relative rise in the
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burden of malarial disease caused by the non-falciparum malarias [18, 19]. This study was con-
ducted to investigate the demographic distribution, morbidity and mortality associated with P.
malariae infection in southern Papua, Indonesia, a malarious region coendemic for four Plas-
modium species–P. falciparum, P. vivax, P.malariae and P. ovale. Understanding the features
of P.malariae infection will be important for guiding clinical management and eventual eradi-
cation of this species.
Methods
Study site
This study was conducted at Rumah Sakit Mitra Masyarakat (RSMM), the major referral hos-
pital in Timika, southcentral Papua, Indonesia. The characteristics of this hospital and the sur-
rounding region have been described in detail elsewhere [20, 21]. In brief, Timika, has a
population of approximately 200,000 people and is situated in the lowlands, about 50km south
of a large copper and gold mine. It has a tropical climate with rainfall occurring year-round
with minimal seasonal variation. Timika has a diverse ethnic population comprised of High-
land Papuans, Lowland Papuans (both of Melanesian descent) and non-Papuans (mostly of
Indonesian descent). Rumah Sakit Mitra Masyarakat has 110 beds, a 24h emergency depart-
ment, a high dependency unit with facilities for intravenous infusions, peritoneal dialysis and
monitoring but not mechanical ventilation, and an outpatient department that sees approxi-
mately 300 patients per day, 6 days per week.
Papua has the highest burden of malaria in Indonesia with an estimated incidence in Timika
of 876 episodes per 1,000 per year (range: 711–906) [20]. High frequencies of drug resistant P.
falciparum and P. vivax strains have been reported [22] although P.malariae remains sensitive
to chloroquine [23]. Malaria transmission is perennial and most intense in the lowland regions.
In view of the high levels of antimalarial drug resistance exhibited by both P. falciparum and P.
vivax, antimalarial policy for uncomplicated malaria due to any Plasmodium species was
changed in March 2006 from oral quinine to dihydroartemisinin-piperaquine, an artemisinin
combination therapy (ACT). In order to monitor the impact of ACT on malaria morbidity and
mortality, a hospital surveillance system was established in 2004 and maintained until 2013.
Data collection procedures
Data from all patient presentations to RSMM between April 2004 and December 2013 were eli-
gible for inclusion in this study. Hospital administrators entered demographic and diagnostic
data into an electronic database (Q-Pro software, Jakarta, Indonesia) for all patients presenting
to the hospital, regardless of department. Data collected included age, gender, ethnicity, preg-
nancy status and diagnoses classified according to the International Classification of Diseases,
version 10. The latter was based on the opinion of the treating physician after clinical investiga-
tion. The results of full blood counts from the hospital’s Coulter Counter were entered auto-
matically into a separate database and prescription data from the hospital pharmacy were
entered manually into a further database by the pharmacist filling the prescription. Records
from all three databases were identified using the patient’s unique hospital identification num-
ber. Previous published analyses have included data from patients presenting to RSMM
between 2004 and the end of 2012 [24, 25].
Hospital guidelines dictated that all febrile patients seen in the outpatients department and
all inpatients regardless of clinical diagnosis had a blood film for malaria. Giemsa-stained thick
and thin films were considered negative after microscopic assessment of 100 high power fields.
Hospital microscopists underwent regular training and quality assurance procedures to ensure
a high standard of microscopy [21].
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Clinical, hematological and prescription data were merged sequentially by creating all possi-
ble pairwise combinations for a given unique hospital identification number. Sets where the
date of the laboratory record or prescription fell between the date of admission and discharge
were retained. In cases where there was more than one hemoglobin or platelet count during a
single presentation, only the lowest value was kept. Both the minimum and the maximum
white cell count were kept. Severe anemia was defined as a hemoglobin less than 5g/dL but in
accordance with 2014 World Health Organization severe malarial anemia definitions, we also
conducted subanalyses in which severe anemia was defined as a hemoglobin<5g/dL in chil-
dren under 12 years of age and<7g/dL in adults12 years of age [26]. Severe thrombocytope-
nia was defined as a platelet count less than 50x103/μL. White cell counts were categorized as
normal or abnormal according to age-specific normal ranges [27].
Statistical analysis
Analyses were performed using STATA version 13.1 (College Station, Texas, USA). Anemia,
thrombocytopenia, admission to hospital and length of stay were used to explore the morbidity
associated with P.malariae infection and were compared between patients infected with P. fal-
ciparum, P. vivax, P. ovale (where numbers allowed) and mixed Plasmodium species infections.
We also examined the frequency of abnormal white cell counts and selected comorbidities to
help establish whether P.malariae infection was likely to have been the sole reason for presen-
tation. Univariable and multivariable logistic regression models (the latter adjusting for age
group (<1 year, 1 to<5 years, 5 to<15 years,15 years), sex, ethnicity (non-Papuan, High-
land Papuan, Lowland Papuan), pregnancy status and white cell count (normal, abnormal)
were used to compare the odds for severe anemia and severe thrombocytopenia between
patients with P.malariae infection and those with infection by the other Plasmodium species
listed above. As individuals in the hospital database could appear more than once, robust stan-
dard errors (Huber-White sandwich estimator) were calculated, accounting for within-patient
correlation. Given the very large numbers of patients in the database, formal tests of statistical
significance were only done in the context of univariable and multivariable logistic regression
models.
Ethical clearance
This study was approved by the Ethics committees of the University of Gajah Mada (Yogya-
karta, Indonesia) and Menzies School of Health Research (Darwin, Australia). All data were
anonymized.
Results
Between April 2004 and December 2013 there were 1,054,674 presentations to RSMM of
which 196,380 (18.6%) were associated with malaria. Plasmodium malariaemonoinfection
accounted for 2.6% of all malaria cases (5,097 presentations made by 4,456 individuals)
(Table 1). Other Plasmodium species present included P. falciparum (100,078 presentations,
51.0%), P. vivax (65,306 presentations, 33.3%), P. ovale (120 presentations, 0.1%) and mixed
Plasmodium species (25,779 presentations, 13.1%). Two hundred and forty one (0.9%) of the
mixed species infections included P.malariae, of which 148 (0.6%) were in combination with
P. falciparum and 93 (0.4%) were with P. vivax. Overall, 4.4% (225/5,097) of presentations with
P.malariaemonoinfection were followed by a further presentation with P.malariae infection
within one year. The median day of representation was 171 (Interquartile Range [IQR] 86–
266) with no significant difference in the crude risk between those treated with oral quinine
and those treated with dihydroartemisinin-piperaquine (5.9% versus 4.4%). Only 1.3%
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(10,886/858,294) of patients without malaria, 1.9% (1,892/100,078) of patients with falciparum
malaria and 1.3% (868/65,306) of patients with vivax malaria represented with P.malariae
infection within a year.
The age distribution of all patients presenting with P.malariaemonoinfection was similar
to P. falciparum (median 21.7 and 20.1 years respectively), but substantially older than for P.
vivax (median 10.0 years) and mixed infections (15.1 years). For all species, there was a
bimodal distribution of age at presentation with a peak in children under 5 years of age and
another in early adulthood. The childhood peak for P.malariae was less pronounced than for
the other species (P. ovale excepted) (see Fig 1). The proportion of malaria presentations attrib-
utable to P.malariae increased from 0.9% (80/8,669) for patients less than one year of age to
3.1% (3,367/107,066) for patients older than 15 years (Fig 2).
The majority of presentations with P.malariae were in Highland Papuans (4,452, 87.3%),
but this predominance was also apparent for the other Plasmodium species (range 81.0–88.3%)
and patients without malaria (67.2%).
Hospitalization, treatment and comorbidity
In total, 8.5% (432/5,097) of the patients with P.malariaemonoinfection required admission
to hospital, less than the proportion for patients with P. falciparum (17.4%) and mixed infec-
tions (15.3%), but similar to those with P. vivax (9.4%) and P. ovale (8.3%) infections. The
median length of stay for those admitted with P.malariae infection was 2.5 days (IQR 2.0–4.0
days); shorter than for those without malaria 3.0 days (IQR 2.0–5.0 days) but longer than for
patients with other Plasmodium species infections (P. falciparum, 2.0 days (2.0–4.0), P. vivax,
2.0 days (2.0–4.0), P. ovale, 2.0 days (1.0–3.0) and mixed species, 2.0 days (2.0–4.0). Admission
for greater than 5 days was required for 17.4% (75/432) of patients with P.malariae infection,
Table 1. Demographic distribution of all 1,054,674 patient presentations.
Species
Negative P. falciparum P. vivax P. ovale P. malariae Mixed species Total
n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Age group
0 to <1 71,789 (8.4) 2,321 (2.3) 5,274 (8.1) 2 (1.7) 80 (1.6) 992 (3.8) 80,458 (7.6)
1 to <5 116,487 (13.6) 16,132 (16.1) 19,859 (30.4) 11 (9.2) 554 (10.9) 6,152 (23.9) 159,195 (15.1)
5 to <15 86,366 (10.1) 19,913 (19.9) 11,340 (17.4) 22 (18.3) 1,096 (21.5) 5,559 (21.6) 124,296 (11.8)
15 583,607 (68.0) 61,707 (61.7) 28,832 (44.1) 85 (70.8) 3,367 (66.1) 13,075 (50.7) 690,673 (65.5)
Sex
Male 378,074 (44.0) 49,592 (49.6) 32,970 (50.5) 68 (56.7) 2,575 (50.5) 13,068 (50.7) 476,347 (45.2)
Female 480,220 (56.0) 50,486 (50.4) 32,336 (49.5) 52 (43.3) 2,522 (49.5) 12,711 (49.3) 578,327 (54.8)
Pregnant
No 399,336 (83.2) 47,808 (94.7) 31,215 (96.5) 49 (94.2) 2,395 (95.0) 12,264 (96.5) 493,067 (85.3)
Yes 80,884 (16.8) 2,678 (5.3) 1,121 (3.5) 3 (5.8) 127 (5.0) 447 (3.5) 85,260 (14.7)
Ethnic group
Non-Papuan 152,502 (17.8) 8,305 (8.3) 7,539 (11.6) 9 (7.5) 164 (3.2) 1,324 (5.1) 169,843 (16.1)
Highland Papuan 576,524 (67.3) 81,706 (81.7) 52,905 (81.1) 106 (88.3) 4,452 (87.3) 22,434 (87.0) 738,127 (70.1)
Lowland Papuan 128,027 (14.9) 9,982 (10) 4,820 (7.4) 5 (4.2) 481 (9.4) 2,015 (7.8) 145,330 (13.8)
Total 858,294 (100) 100,078 (100) 65,306 (100) 120 (100) 5,097 (100) 25,779 (100) 1,054,674 (100)
Abbreviations: n, number
Age data were missing in 52 cases, and ethnicity data were missing in 1,374 cases
doi:10.1371/journal.pntd.0004195.t001
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19.4% (13,130/67,365) of those without malaria, 11.2% (1,942/17,387) with P. falciparum,
13.0% (795/6,116) with P. vivax, 10.0% (1/10) with P. ovale and 12.0% (473/3,945) with mixed
species infections. Assuming 100% bed occupancy over the study period, patients with P.
malariae infection accounted for 0.4% (1,733/391,710) of total hospital bed occupancy. The
corresponding figures for the other Plasmodium species were 14.6% (57,037 bed days) for P.
falciparum, 5.4% (21,298 bed days) for P. vivax, 0.006% (24 bed days) for P. ovale and 3.4%
(13,241 bed days) for mixed species infections.
Fig 1. Age distributions of patients presenting to RSMM by Plasmodium species. Vertical lines
represent median age.
doi:10.1371/journal.pntd.0004195.g001
Plasmodiummalariae Infection and Severe Anemia
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004195 December 31, 2015 6 / 16
Overall, 4,691 (92.0%) patient presentations with P.malariae infection were matched with
corresponding pharmacy data. In 4,459 of these cases (95.1%), treatment was with oral therapy
alone. Prior to March 2006 (401 cases), the majority of patients received either oral quinine
(n = 212; 52.9%), chloroquine (n = 76; 19.0%) or doxycycline (n = 71, 17.7%) with small num-
bers receiving sulphadoxine-pyrimethamine (n = 21, 5.2%). After the change of malaria treat-
ment protocols to ACT in March 2006 (4,290 cases), 4,157 (96.9%) were treated with ACT
(3,898 (90.9%) with dihydroartemisinin-piperaquine and 261 (6.1%) with artesunate-amodia-
quine (two patients received both combinations)). In 232 cases (4.9%), patients with P.malar-
iae were treated with parenteral therapy; intravenous quinine prior to April 2006 (23 cases,
9.9%) and intravenous artesunate after this date (209 cases, 90.1%).
Of the 5,097 presentations with P.malariaemonoinfection, 1,516 (29.7%) were associated
with at least one additional clinical diagnosis and this figure rose to 96.5% (417 presentations)
in those admitted to hospital. The overall proportions with comorbidity for those with P. falcip-
arum, P. vivax and mixed infections were slightly higher: 32.7%, 30.5% and 31.0% respectively.
Thirty (0.6%) patients with P.malariae infection presented following trauma and therefore
presumably had incidental parasitemias (Table 2). Overall, 16 (0.3%) of the patients with P.
malariae infection had documented renal disease, of whom 4 (0.1%) were recorded as having
nephrotic syndrome. Although numbers were small, this proportion was approximately
10-fold higher than for the other Plasmodium species (Table 2). All four of the patients with P.
malariae infection and nephrotic syndrome were under the age of 15 years and three were
Fig 2. Percent of malaria cases due to Plasmodiummalariae by age, with polynomial fit line. Age truncated at 70 years to maintain stability of fit line.
doi:10.1371/journal.pntd.0004195.g002
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under the age of 5 years giving a risk of nephrotic syndrome of 0.23% (95% Confidence Interval
[95%CI]; 0.06% to 0.59%) in children under 15 years and 0.47% (95%CI; 0.10% to 1.4%) in
children aged under 5 years old. None of the 4 patients with nephrotic syndrome died at the
hospital prior to the end of the study.
Hematological morbidity
Hemoglobin concentrations, platelet counts and white cell counts were available in 22.9%
(241,594), 22.4% (236,536) and 22.7% (239,444) of all patient presentations with the corre-
sponding figures for P.malariae cases being 34.3% (1,750), 33.6% (1,713) and 34.1% (1,739)
respectively. The mean hemoglobin concentration was 9.0 g/dL in patients with P.malariae
infection, the lowest of all the Plasmodium species (10.6g/dL for those without malaria, 9.5g/dL
for P. falciparum, 9.6g/dL for P. vivax, and 9.3g/dL for mixed species infections). Overall, 5.7%
(n = 100) of patients presenting with P.malariae infections had a hemoglobin<5g/dL (32/577
[5.5%] of those<12 years and 68/1,173 [5.8%] of those12 years). This was similar to the
crude proportions for P. falciparum and P. vivax (Table 3). Three hundred and sixty nine
(21.1%) patients with P.malariaemalaria had hemoglobin concentrations under 7g/dL (151/
577 [26.2%] of those<12 years and 218/1,173 (18.6%) of those12 years) and 1,128 (64.5%)
had a hemoglobin under 10g/dL. After controlling for confounding factors, those with P.
malariae infection were at significantly greater risk of severe anemia compared to those with-
out Plasmodium infection both when defined as a hemoglobin of less than 5g/dL (Adjusted
Odds Ratio [AOR]; 2.29, 95%CI; 1.85–2.84, P<0.001, Table 4) and as per 2014 WHO criteria
(AOR; 2.02, 95%CI; 1.75–2.33, P<0.001) [26].
The mean platelet count in patients with P.malariae infection was 142.7x103/μL, compared
to 130.4x103/μL for P. falciparum, 166.8x103/μL for P. vivax and 131.6x103/μL for mixed spe-
cies infection. Severe thrombocytopenia (platelet count<50x103/μL) was present in 123 (7.2%)
patients with P.malariae (Table 3) and very severe thrombocytopenia (platelet count
Table 2. Comorbidities in patients presenting to Rumah Sakit Mitra Masyarakat by Plasmodium species.
Species
Negative P. falciparum P. vivax P. ovale P. malariae Mixed species Total
n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Pneumonia
No 834,991 (97.3) 98,983 (98.9) 64,368 (98.6) 119 (99.2) 5,053 (99.1) 25,436 (98.7) 1,028,950 (97.6)
Yes 23,303 (2.7) 1,095 (1.1) 938 (1.4) 1 (0.8) 44 (0.9) 343 (1.3) 25,724 (2.4)
Renal Disease
No 855,722 (99.7) 99,663 (99.6) 65,225 (99.9) 120 (100) 5,081 (99.7) 25,695 (99.7) 1,051,506 (99.7)
Yes 2,572 (0.3) 415 (0.4) 81 (0.1) 0 (0) 16 (0.3) 84 (0.3) 3,168 (0.3)
Nephrotic syndrome
No 858,117 (99.98) 100,072 (99.99) 65,302 (99.99) 120 (100) 5,093 (99.9) 25,776 (99.99) 1,054,480 (99.98)
Yes 177 (0.02) 6 (0.01) 4 (0.01) 0 (0) 4 (0.1) 3 (0.01) 194 (0.02)
HIV
No 840,095 (97.9) 99,498 (99.4) 65,029 (99.6) 119 (99.2) 5,072 (99.5) 25,661 (99.5) 1,035,474 (98.2)
Yes 18,199 (2.1) 580 (0.6) 277 (0.4) 1 (0.8) 25 (0.5) 118 (0.5) 19,200 (1.8)
Trauma
No 800,208 (93.2) 99,664 (99.6) 65,046 (99.6) 120 (100) 5,067 (99.4) 25,708 (99.7) 995,813 (94.4)
Yes 58,086 (6.8) 414 (0.4) 260 (0.4) 0 (0) 30 (0.6) 71 (0.3) 58,861 (5.6)
Abbreviations: n; number, HIV; human immunodeﬁciency virus
doi:10.1371/journal.pntd.0004195.t002
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<20x103/μL) in 16 (0.9%) cases. None of the patients with platelet counts<50x103/μL) were
recorded as having clinical evidence of bleeding. After controlling for confounding factors, P.
malariae infection was associated with a two-fold higher odds of severe thrombocytopenia
compared to those with no malaria (AOR; 2.34, 95%CI; 1.93–2.83, P<0.001) (Table 4).
Overall 34.4% (n = 598) of patients with P.malariae infection had an abnormal age-adjusted
white cell count; a similar proportion to patients infected with the other Plasmodium species,
but lower than that in patients without malaria (42.9%, P<0.001). In 36.8% of cases the abnor-
mal white cell count was above the age-adjusted normal range and in the remaining 63.2% it
was below the normal range.
Mortality
In total, 0.3% (16/5,097) of patients with P.malariae infection died compared to 0.5% (4,254/
858,294) of those without malaria, 0.4% (376/100,078) with P. falciparum, 0.2% (130/65,306)
with P. vivax, none with P. ovale and 0.3% (73/25,779) with mixed infections. The correspond-
ing risk of mortality for patients who were admitted to hospital or seen in the emergency
department was 2.4% (16/663) for P.malariae, 3.4% (4,244/125,375) for those without Plasmo-
dium infection, 1.6% (375/23,304) for P. falciparum, 1.4% (129/8,937) for P. vivax and 1.6%
(73/4,608) for mixed infections. The median age of the 16 patients who died with P.malariae
parasitemia was 23.4 years (Range; 5.6 to 50 years, IQR; 17.0–41.9 years), with a risk of mortal-
ity of 1/1,481 (0.07%) in children<12 years and 15/3,616 (0.4%) in adults12 years. Nine
(56.3%) of the patients who died were male, 4 (26.7%) had a hemoglobin<5g/dL and 6 (40%)
had severe anemia according to 2014 WHO criteria (Table 5). Two patients (14.3%) had severe
thrombocytopenia and 10 (71.4%) had an abnormal white cell count (9 patients (90%) had a
value that was above the normal range during their admission and three (30%) had a value that
was below the normal range). Five (31%) patients were recorded as having concomitant
tuberculosis.
Discussion
This large case series from southern Papua shows that P.malariae is responsible for a minority
(2.6%) of clinical malaria cases but has potential to cause significant morbidity. Compared to
Table 3. Proportions with severe anemia (hemoglobin <5g/dL), severe thrombocytopenia (platelet count <50 x103/μL) and abnormal white cell
count by Plasmodium species.
Severe anemia Severe thrombocytopenia White cell count
Species Hb 5g/dL,
n (%)
Hb <5g/dL,
n (%)
WHO criteria*,
n (%)
Plt 50x103/μL,
n (%)
Plt <50 x103/μL,
n (%)
Normal,
n (%)
Abnormal,
n (%)
Negative 163,650 (97.5) 4,136 (2.5) 12,051 (7.2) 159,755 (97.3) 4,417 (2.7) 94,929 (57.1) 71,224 (42.9)
P. malariae 1,650 (94.3) 100 (5.7) 250 (14.3) 1,590 (92.8) 123 (7.2) 1,141 (65.6) 598 (34.4)
P. falciparum 37,585 (93.7) 2,521 (6.3) 4,851 (12.1) 33,353 (85.0) 5,905 (15.0) 26,956 (67.8) 12,812 (32.2)
P. vivax 21,085 (95.0) 1,099 (5.0) 1,805 (8.1) 20,044 (92.0) 1,743 (8.0) 15,422 (69.9) 6,644 (30.1)
P. ovale 31 (100) 0 (0) 3 (9.7) 28 (93.3) 2 (6.7) 21 (72.4) 8 (27.6)
Mixed
species
8,955 (92.0) 782 (8.0) 1,239 (12.7) 8,345 (87.1) 1,231 (12.9) 6,674 (68.9) 3,015 (31.1)
Total 232,956 (96.4) 8,638 (3.6) 20,199 (8.4) 223,115 (94.3) 13,421 (5.7) 145,143
(60.6)
94,301 (39.4)
Abbreviations: n; number, WHO; World Health Organization, Hb; hemoglobin, Plt; platelet
* Hemoglobin < 5g/dL in children under 12 years old and <7g/dL in adults 12 years old
doi:10.1371/journal.pntd.0004195.t003
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patients infected with other Plasmodium species, those with P.malariae infection had a lower
mean hemoglobin concentration and a similar risk of being admitted to hospital (8.5%) or
dying (0.3%). Overall P.malariaemalaria accounted for almost 0.5% of hospital bed
occupancy.
Patients with P.malariae infections tended to be older than those with non P.malariae
malaria, particularly compared to those with P. vivaxmono- or mixed infections. This probably
reflects the low transmission intensity in this area. Whereas the majority of children in Timika
are likely to have been infected with P. vivax by the age of 5 years (and therefore have started to
acquire immunity early in life), fewer than one in ten children could be expected to have been
infected with P.malariae by the same age (based on an estimated annual incidence of 15.7
cases per 1,000 persons in 2005) [20]. Plasmodium malariae has a predilection for senescent
red blood cells whereas P. vivax preferentially infects young red cells, in particular reticulocytes
[28, 29]. It is therefore possible that during the very early stages of infancy there is a biological
predisposition to vivax malaria and a relative protection against P.malariae infection.
Table 4. Univariable andmultivariable logistic regressionmodels of the risk factors for severe anemia (hemoglobin <5g/dL) and severe thrombo-
cytopenia (platelet count <50 x103/μL).
Severe anemia (Hb<5g/dL) Severe thrombocytopenia (Plt<50x103/μL)
Risk factor Crude OR (95%CI) P AORa (95%CI) P Crude OR (95%CI) P AORa (95%CI) P
Species
Negative ref - ref - ref - ref -
P. malariae 2.40 (1.94–2.96) <0.001 2.29 (1.85–2.84) <0.001 2.80 (2.32–3.38) <0.001 2.34 (1.93–2.83) <0.001
P. falciparum 2.65 (2.51–2.81) <0.001 2.24 (2.11–2.38) <0.001 6.40 (6.07–6.76) <0.001 6.20 (5.86–6.55) <0.001
P. vivax 2.06 (1.92–2.22) <0.001 2.03 (1.89–2.19) <0.001 3.15 (2.94–3.37) <0.001 3.88 (3.62–4.15) <0.001
Mixed species 3.46 (3.18–3.76) <0.001 3.58 (3.28–3.91) <0.001 5.34 (4.95–5.75) <0.001 5.86 (5.42–6.34) <0.001
Age group
<1 year 0.98 (0.89–1.08) 0.6 1.02 (0.92–1.12) 0.8 0.44 (0.41–0.48) <0.001 0.47 (0.43–0.52) <0.001
1 to <5 years 1.58 (1.48–1.69) <0.001 1.25 (1.16–1.34) <0.001 0.46 (0.43–0.49) <0.001 0.31 (0.28–0.33) <0.001
5 to <15 years 1.49 (1.37–1.61) <0.001 1.15 (1.06–1.25) 0.001 0.80 (0.75–0.85) <0.001 0.48 (0.45–0.51) <0.001
15 years ref - ref - ref - ref -
Gender
Male ref - ref - ref - ref -
Female 1.05 (0.99–1.11) 0.1 -b - 0.76 (0.72–0.79) <0.001 - b -
Pregnancy status
Not pregnant ref - 1.17 (1.10–1.24) b <0.001 ref - 0.75 (0.71–0.79)b <0.001
Pregnant 0.62 (0.57–0.68) <0.001 0.99 (0.89–1.10) b 0.9 0.65 (0.60–0.71) <0.001 0.61 (0.55–0.66)b <0.001
Ethnic Group
Non-Papuan ref - ref - ref - ref -
Highland Papuan 4.22 (3.75–4.74) <0.001 3.89 (3.45–4.38) <0.001 3.06 (2.83–3.30) <0.001 2.89 (2.66–3.14) <0.001
Lowland Papuan 2.64 (2.30–3.04) <0.001 2.52 (2.18–2.91) <0.001 0.87 (0.78–0.97) 0.02 0.99 (0.89–1.12) 0.9
White cell count
Normal ref - ref - ref - ref -
Abnormal 1.85 (1.77–1.94) <0.001 2.07 (1.97–2.18) <0.001 1.34 (1.29–1.39) <0.001 1.77 (1.70–1.85) <0.001
Abbreviations: OR; odds ratio, AOR; adjusted odds ratio, Hb; hemoglobin, Plt; platelet
a Multivariable models also include year of presentation
b In the multivariable model, a non-ordered, 3-category variable incorporating sex and pregnancy status was used. Male sex is the reference category.
doi:10.1371/journal.pntd.0004195.t004
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A major finding of our study (and one that was also noted in an earlier published analysis
from this region [24]) is the association between P.malariae parasitemia and substantial hema-
tological morbidity. The mean hemoglobin in patients with P.malariae infection was 0.3–0.6g/
dL lower than the other locally prevalent Plasmodium species with an associated 2.3-fold
greater odds of severe anemia compared to individuals without malaria. There are several
potential explanations for this finding. Plasmodium malariae replicates slowly and does not
typically reach high parasitemias [29]. Prolonged infection is therefore more likely to have
Table 5. Hematological parameters and recorded comorbidities in the 16 patients who died with Plasmodiummalariae parasitemia.
Patient
Number
Sex Age
(years)
Length of
stay (days)
Minimum hemoglobin
concentration (g/dL)
Platelet count
(x103/μL)
Most abnormal white
cell count (cells/μL)
Other recorded
diagnoses
1. M 33.7 6 2.7 146 6,100 Ischaemic
cardiomyopathy
Congestive heart failure
Non-inﬂammatory
pericardial effusion
Pneumonia
2. M 22.6 13 9.6 182 2,600 HIV
Tuberculous meningitis
Gastroenteritis
3. M 37.6 0.5 11.1 343 16,800 Pulmonary tuberculosis
4. M 21.3 9 3.1 53 13,100 Acute renal failure
5. F 12.2 3 7.8 199 29,000 Malnutrition
Helminthiasis
Pulmonary tuberculosis
6. F 18 0.5 - - - -
7. F 18.7 1 11.9 93 10,500 Pulmonary tuberculosis
Gastroenteritis
Urinary tract infection
8. F 12 0.5 3.3 - 15,600 -
9. M 49.1 0.5 6.7 23 14,700 Pneumonia
Non-infective
gastroenteritis
Chronic renal failure
10. F 46.1 1 11 44 4,100 Pulmonary tuberculosis
Gastroenteritis
11. F 16 6 4.8 339 13,200 Chronic renal failure
12. M 24.1 0 7.2 140 6,000 -
Pneumonia
Adult Respiratory Distress
Syndrome
14. M 50 1 6.9 128 8,300 Pneumonia
Chronic renal failure
Suspected tuberculosis
Inguinal hernia
Ascites
15. M 5.6 3 11.1 56 3,500 Encephalomyelitis
16. F 48 0 10.6 156 - -
Abbreviations: F = female, M = male
doi:10.1371/journal.pntd.0004195.t005
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been present in patients presenting with this disease compared to those with P. falciparum or
P. vivax infections. A chronic, low-level parasitemia resulting in ongoing destruction of both
parasitized but, more importantly, non-parasitized red cells as well as marrow dyserythropoi-
esis may have a cumulative effect on lowering hemoglobin concentrations. Previous observa-
tion of malariatherapy patients treated with P.malariae infection demonstrated that those with
naturally-induced infections typically had a nadir in hemoglobin concentration between day
30 and 90 of infection with only a slight improvement in concentrations thereafter [16]. Recent
data suggest that the low circulating parasitemias found in P. vivax infection significantly
underestimate total parasite biomass [30]. While speculative, it is possible that a hidden, non-
circulating parasite biomass may also be present in P.malariae, capable of contributing to a
degree of anemia out of proportion to circulating parasitemia.
It is also possible that the significant anemia seen with P.malariae infection is partially a
result of comorbid conditions as opposed to the infection itself. However, given the similar fre-
quency of major comorbidities such as pneumonia, renal disease and HIV compared with the
other species, a major bias from differential rates of comorbidities seems unlikely. Finally,
Highland Papuans are the ethnic group with the highest risk of severe anemia in Timika–possi-
bly due to nutritional factors, red cell and hemoglobin abnormalities or gastrointestinal hel-
minth infection. Whether for geographical or biological reasons, a particularly high proportion
of P.malariae patients were highlanders, potentially contributing to the lower mean hemoglo-
bin seen in these patients. After adjusting for various risk factors, including ethnicity, in the
multivariable model, the risk of severe anemia in P.malariae infections was similar to that for
P. falciparum and P. vivaxmonoinfections.
The low incidence of P.malariae infection and relatively high burden of falciparum and
vivax malaria means that the latter species are more common causes of severe anemia and
therefore more important targets for public health intervention. Nevertheless, on an individual
basis, those with P.malariae parasitemia need to be investigated for anemia and treated aggres-
sively if present. In this context, the relatively high rates of representation with P.malariae
over the subsequent year (~4%), raises the possibility of partial response to ACT treatment
coupled with prolonged subclinical carriage. There have been few studies of ACT drug efficacy
in P.malariae and most have had only 28 days of follow-up [31]. Further efficacy studies with
longer follow-up are warranted.
Nephrotic syndrome, a well-recognized complication of P.malariae infection, is mostly
described in children living in endemic areas [32] with few cases reported since the mid-1970s
[32–34]. Renal biopsies in two recent cases have shown chronic membranous glomerulopathy
[34] and mesangioproliferative glomerulonephritis respectively [33]. The syndrome has been
reported as being hard to treat and often unresponsive to corticosteroids, immunosuppressive
agents and antimalarial drugs [35]. Given the lack of access to advanced diagnostic techniques
in Timika, the diagnoses of nephrotic syndrome must be treated with caution. Moreover, we
cannot infer that there was necessarily a causal relationship between the P.malariae infections
and nephrotic syndrome. Nevertheless, we have, for the first time been able to estimate the risk
of this condition at 1 in 200 presentations to hospital for children with P.malariae infection
under the age of 5 years. None of the 4 patients with nephrotic syndrome and P.malariae
infection were reported to have died during the follow-up period however 3 of the 16 patients
who died were recorded as having chronic renal failure (not further specified) and one had
acute renal failure. Unfortunately we did not have access to information on the presence or
absence of albuminuria (a common finding in malariatherapy patients treated with P.malariae
infections in the 1930s [16]).
A similar proportion of all patients presenting to hospital with P.malariae infection died as
compared to patients with infection by the other Plasmodium species–a surprising finding
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given the supposedly low virulence of this species. The same was true of the subset of patients
with P.malariae who were admitted to hospital. Based on the data at hand, we cannot make
inferences on whether there was a causal link between the P.malariae infections and death.
Fourteen of the deceased patients had a white cell count measurement during their final admis-
sion and in 9 cases, this was above the age-appropriate normal range. We were unable to find
data on the typical impact of P.malariae infection on white cell counts. The high proportion of
the deceased patients with leucocytosis could reflect the greater inflammatory response seen in
severe malaria from all species [30, 36] and/or concomitant bacterial sepsis. Bacterial coinfec-
tion was certainly recorded in several cases. Severe anemia was only present in a quarter of the
patients with P.malariae who died (40% if WHO criteria were used) and thus was not the sole
attributable cause of death.
Plasmodium malariae’s tendency to cause prolonged asymptomatic and/or subpatent infec-
tions will confound elimination strategies that are based on active case detection or mass
screening and treatment. Chronically infected patients with low-level parasitemia probably
have substantial transmission potential and therefore mass drug administration campaigns
could potentially have a significant impact on this species. Given the older age distribution of
patients infected with P.malariae, it would be important to deliver the antimalarial drug to all
age groups rather than just children.
Some important limitations of our study should be considered. Malaria diagnosis and spe-
cies identification was based on microscopy alone (except for a small number of P. falciparum
cases confirmed using rapid diagnostic tests), and parasitemia quantitation was not available.
Previous studies have clearly demonstrated that microscopic diagnosis of P.malariae signifi-
cantly underestimates the true prevalence of parasitemia when compared with PCR-based
diagnosis and that correctly differentiating between P.malariae and P. falciparum based on
morphology alone is fraught with error [37, 38]. A previous comparison between hospital and
research laboratory microscopy results at RSMM showed 68.4% concordance in the diagnosis
of P.malariaemonoinfection with 5.3% of P.malariae cases actually deemed to be mixed P.
malariae/P. falciparum infections and 26.3% of cases originally diagnosed as mixed P.malariae
infections reclassified as P.malariae monoinfections [21]. Plasmodium malariae infection is
often asymptomatic or minimally symptomatic, it is therefore likely that a smaller proportion
of individuals infected with this species in the community presented to hospital for assessment
and treatment when compared to infections by the other Plasmodium species. A potentially
large ascertainment bias will therefore have occurred leading to an underestimation of the true
prevalence and burden of P.malariae parasitemia in this region. Previous studies have shown
that subpatent infection with Plasmodium species is associated with under-recognised morbid-
ity (as well as ongoing risk of transmission), mostly in the form of chronic anemia [39–42].
The small fee charged to non-Papuans for care may have discouraged them from accessing
the hospital services resulting in a degree of selection bias in our study. Consequently those of
Papuan ethnicity were undoubtedly over-represented. Selection bias is also likely to have
occurred in our analysis of hematological parameters as hemoglobin measurements were done
according to the orders of the treating clinician rather than routinely in all patients. Patients
without malaria were less likely to have had a full blood count. Since those who did not have a
full blood count were presumably less likely to have been severely anaemic, our analyses will
have underestimated the relative impact of malaria on hemoglobin concentrations in the study
population. In exploring the anemia associated with Plasmodium infection we were unable to
control for some potentially important confounders. We had no information on parasite quan-
titation/parasite biomass, the prevalence of hemoglobinopathies and red cell disorders such as
G6PD deficiency or thalassemia and we were unable to control for factors such as malnutrition,
iron deficiency and worm infestation, all of which are known to contribute significantly to
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anemia [43, 44]. It is highly probable that some of the anemia detected in those with P.malar-
iae parasitemia was contributed to by these factors leading to an over-estimation of the species’
impact on hemoglobin concentrations. Any variations in the prevalence of these comorbid
conditions in different regions will also limit the generalizability of our findings.
In conclusion, we have shown that although P.malariae is responsible for a small propor-
tion of malaria infections in Papua, it is associated with appreciable morbidity and also mortal-
ity. This verifies the clinical relevance of infection with non-falciparum Plasmodium species
and emphasizes the importance of attempting to eradicate all species infecting humans. The
low parasite densities, high incidence of asymptomatic disease and the longevity of P.malariae
infections are likely to present significant barriers to elimination of this species.
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